Complex Regional Pain Syndrome (CRPS) Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The complex regional pain syndrome (CRPS) market is expected to register a CAGR of 2.1% over the forecast period.

The complex regional pain syndrome market has been significantly impacted by the COVID-19 pandemic, particularly in its early stages. COVID-19 infection causes peripheral nerve lesions, including small fiber neuropathy. The potentially disabling complication of any peripheral nerve lesion is complex regional pain syndrome (CRPS). For instance, a study report published by PubMed in November 2021, stated that systemic hyperinflammation in severe COVID-19 may contribute to peripheral and central neuronal sensitization, which may increase the risk of developing complex regional pain syndrome (CRPS). As a result of the COVID-19 effect on neuronal sensitization, the demand for drugs used in complex regional pain had witnessed a positive impact. Thus, the impact of COVID-19 on the market was adverse in its initial stages owing to supply chain constraints. However, as the pandemic has subsided, the market is expected to have stable growth during the forecast period of the study.

The major growth drivers of the complex regional pain syndrome market over the forecast period are the rising incidence of complex regional pain syndrome and the growing number of patients suffering from chronic pain. For instance, as per the study published by PubMed in September 2021, the worldwide prevalence of complex regional pain syndrome varies from 5.5 to 26.2 per 100,000 people per year. Also, as per the report published by PubMed in July 2021, the general CRPS incidence rate was 15.83 per 100,000, with 19.5 for type 1 and 12.1 for type 2. Also, the increase in chronic pain among patients influences the market growth. For instance, as per the report published by PubMed in September 2021, the prevalence of pain is 60%, 48% for chronic pain, and 10% for neuropathic pain among chronic kidney disease patients. Thus, with the significantly high incidence rate and increase of chronic pain among patients, the demand for complex regional pain syndrome treatment is expected to increase, which is anticipated to have a positive impact on the growth of the studied market during the forecast period.

Moreover, with increasing product launches the market is expected to experience growth during the forecast period of the study. For instance, in October 2021, PharmaTher Holdings Ltd. received the United States FDA orphan drug designation (ODD) for ketamine in the treatment of complex regional pain syndrome (CRPS), a rare chronic pain and inflammatory condition following an injury to a limb (arm, leg, hand or foot).

Hence, due to the aforementioned factors such as the rising incidence of complex regional pain syndrome, the growing number of patients suffering from chronic pain, and increasing product launches, the market is expected to experience growth over the forecast period of the study. However, a lack of awareness about the target disease in developing countries is expected to restrain the complex regional pain syndrome market during the forecast period.

Key Market Trends

Spinal Cord Stimulation Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period

A spinal cord stimulator is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain. As CRPS involves severe chronic pain, a spinal cord stimulator is effective and safe with minimal to no side effects in relieving the pain of CRPS. The spinal cord stimulation segment is expected to witness significant growth over the forecast period owing to factors such as increasing cases of chronic pain and increasing adoption of technologically advanced products.

According to the data updated by NCBI in July 2022, the spinal cord stimulation technique uses pulsed electrical energy near the spinal cord to manage pain and it has proven its efficacy in refractory and difficult-to-treat pain syndromes. Thus, the increasing adoption of spinal cord stimulation and is likely to enhance segment growth.

New product approvals and launches under this segment drive the growth of the market segment. For instance, in January 2022, Nevro Corp received approval for expanded labeling for its Senza Spinal Cord Stimulation (SCS) System from the United States FDA for the treatment of Non-Surgical Refractory Back Pain (NSRBP). Furthermore, in January 2021, Boston Scientific launched a limited market release of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems.

Therefore, due to the above-mentioned factors such as increasing adoption of spinal cord stimulation, increasing prevalence of chronic pain, and new product approvals and launches, the spinal cord stimulation market segment is expected to grow over the forecast period of the study.

North America is Expected to Hold a Significant Share in the Market Over the Forecast Period

North America is expected to hold a major market share in the complex regional pain syndrome market. The primary factors behind the large market size are the rising prevalence of complex regional pain syndrome and high public and private healthcare spending, which are stimulating the growth of the region.

Moreover, easy access to quality healthcare, favorable reimbursement policies, a strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America. According to the study report published by PubMed in June 2022, the minimum Canadian incidence of complex regional pain syndrome is estimated at 1.14 per 100,000 children per year, and the highest among girls 12 years and older at 3.10 per 100,000. Thus, the high incidences of complex regional pain syndrome will drive the market during the study period.

New product approvals and launches will drive the growth of the complex regional pain syndrome market further. For instance, in September 2021, Soin Therapeutics received orphan drug status from the United States FDA for low-dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS). Furthermore, in February 2021, Zydus Cadila received final approval from the United States FDA to market Nortriptyline Hydrochloride capsules USP, in strengths of 10 mg, 25 mg, 50 mg, and 75 mg.

Thus, the increasing cases of complex regional pain syndrome, and increasing company activities in the region are expected to augment the market growth over the forecast period.

Competitive Landscape

The complex regional pain syndrome market is slightly fragmented in nature due to the presence of several companies operating globally. The major players include Abbott., Boston Scientific Corporation, GSK plc, ICU Medical, Johnson & Johnson Services, Inc., Medtronic, Viatris Inc, Nevro Corp., Purdue Pharma, and Sanofi among others. The players operating in the market focus on introducing new products to address the changing need of the patients.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.